France Preclinical Cro Market Size & Outlook, 2026-2033
The preclinical cro market in France is expected to reach a projected revenue of US$ 648.5 million by 2033. A compound annual growth rate of 8.5% is expected of France preclinical cro market from 2026 to 2033.
Eurofins Scientific SE, Icon PLC, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Thermo Fisher Scientific Inc, Intertek Group PLC, Labcorp Holdings Inc, Crown Bioscience, SGA
Other key industry trends
In terms of revenue, France accounted for 5.0% of the global preclinical cro market in 2025.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In Europe, UK preclinical cro market is projected to lead the regional market in terms of revenue in 2033.
UK is the fastest growing regional market in Europe and is projected to reach USD 1,027.9 million by 2033.
An efficient healthcare & reimbursement system and a large patient pool made the country a preferred location for outsourcing clinical trials. There are hospitals specializing in management of patients undergoing clinical trials across the country.
Moreover, the government is also taking active measures to reduce the approval time of drugs in the clinical trials, which is likely to enhance the market growth. The presence of key pharmaceutical companies like Sanofi, Roche, and Novartis in the country further contributes to the market growth in France.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Preclinical CRO Market Outlook will help companies and investors design strategic landscapes.
Preclinical Optimization, Efficacy & Pk/Pd was the largest segment with a revenue share of 34.89% in 2025.
Horizon Databook has segmented the France preclinical cro market based on target discovery, preclinical optimization, efficacy & pk/pd, ind-enabling safety (glp), bioanalysis & analytics, early cmc / phase i–ii supply covering the revenue growth of each sub-segment from 2021 to 2033.
An efficient healthcare & reimbursement system and a large patient pool made the country a preferred location for outsourcing clinical trials. There are hospitals specializing in management of patients undergoing clinical trials across the country.
Moreover, the government is also taking active measures to reduce the approval time of drugs in the clinical trials, which is likely to enhance the market growth. The presence of key pharmaceutical companies like Sanofi, Roche, and Novartis in the country further contributes to the market growth in France.
France Preclinical Cro Market Development Stage Outlook (Revenue, USD Million , 2021-2033)
Target Discovery
Preclinical Optimization, Efficacy & PK/PD
IND-Enabling Safety (GLP)
Bioanalysis & Analytics
Early CMC / Phase I–II Supply
France Preclinical Cro Market Indication Outlook (Revenue, USD Million , 2021-2033)
Oncology
CNS
Infectious Diseases
Cardiovascular Diseases
Metabolic Disorders
Rare Diseases
Others
France Preclinical Cro Market End Use Outlook (Revenue, USD Million , 2021-2033)
Pharmaceutical and Biopharmaceutical Companies
Medical Device Companies
Academic and Research Institutes
Others
Reasons to subscribe to Preclinical CRO Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Preclinical CRO Market Outlook databook
Our clientele includes a mix of Preclinical CRO Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the France Preclinical CRO Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into France Preclinical CRO Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.